Accessibility Menu
Bone Biologics logo

Bone Biologics(NASDAQ) BBLG

Current Price$1.09
Market Cap$1.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-100%
1 Year-65%
1 Month-22%
Bone Biologics last closing stock price
MetricPriceDate
Last closeUSD 1.082026-07-23
Bone Biologics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10%USD 1.202026-07-16
1 month-21.74%USD 1.382026-06-23
3 month-20.59%USD 1.362026-04-24
Year to date-25.52%USD 1.452025-12-31
1 year-64.71%USD 3.062025-07-23
3 year-98.44%USD 69.122023-07-24
5 year-100%USD 27,000.362021-05-10
Since inception-100%USD 147,599.882016-03-31

Bone Biologics Financials at a Glance

Market Cap

$1.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.86M

EPS (TTM)

-$2.51

P/E Ratio

-0.43

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$1.09

Volume

170

Open

$1.11

Previous Close

$1.08

Daily Range

$1.08 - $1.11

52-Week Range

$1.05 - $4.13

Estimated Earnings Date

Aug 13, 2026

BBLG News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bone Biologics

Bone Biologics develops medical devices to help bone healing in spine surgeries. Its main product aims to support adults with degenerative disc disease. The company’s work targets better recovery for patients needing spinal fusion procedures.

Bone Builders: Products and Services

  • NELL-1/DBM Fusion Device: A combination of a human protein and processed bone material, designed for spinal fusion in adults with degenerative disc disease. (0% of revenue; no sales to date)
  • NB1 Bone Graft Device: A similar product under clinical study, targeting bone growth in spinal surgeries. (0% of revenue; no sales to date)
  • Platform Technology: Potential use in orthopedic, neurosurgery, and sports medicine procedures, aiming to improve bone healing. (0% of revenue; no sales to date)
  • Licensing: Exclusive rights from UCLA to develop and commercialize NELL-1 for spinal fusion. (0% of revenue; no sales to date)

Growth Spurts: Expansion Moves

  • Secured exclusive global license from UCLA for NELL-1 technology (year not specified).
  • Launched pilot clinical study in Australia for NB1 device in 2024.
  • Raised $4.35 million in a public offering in June 2025 to fund development.
  • Filed new patent application for NELL-1 compositions in Q2 2025.
  • Completed a 1-for-6 reverse stock split in June 2025 to maintain Nasdaq listing.

What Makes Bone Biologics Stand Out

The company focuses on a single, patented technology for targeted bone growth. Its device combines a human protein with bone material, aiming for precise bone healing. All research and development is centered on spinal fusion, with no commercial sales yet.

Five Things You Need to Know

  • Revenue was $0 for Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Net loss was $-740,519 in Q2 2025, a 5.5% improvement from Q2 2024.
  • Cash was $6.6 million as of June 30, 2025, up from $3.3 million at year-end 2024.
  • Operating expenses were $748,075 in Q2 2025, down 7.6% from Q2 2024.
  • All funding to date has come from equity offerings; there was no debt financing or commercial revenue as of June 2025.

Bottom Line

Bone Biologics remains in the clinical stage, focused on a single technology for spinal fusion. The company relies on external funding and faces ongoing regulatory and financial challenges.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Jeffrey Frelick, MBA

Website

www.bonebiologics.com

Headquarters

Burlington, MA 01803, US

BBLG Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-50.45%

Return on Capital

-60.16%

Return on Assets

-57.40%

Earnings Yield

-2.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.81M

Volume

170

Avg. Volume

59.06K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$3.00M

EBITDA

-$2.14M

Operating Cash Flow

-$2.57M

Capital Expenditure

-$5.00

Free Cash Flow

-$2.57M

Cash & ST Invst.

$4.53M

Total Debt

$0.00

Bone Biologics Performance Analysis

Bone Biologics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Bone Biologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Bone Biologics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -187.16-63.4%
20232023-12-31USD -204.059.0%
20242024-12-31USD -28.97-85.8%
20252025-12-31USD -2.65-90.9%
Bone Biologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-315.6%
Q32025-09-3072.2%
Q42025-12-31-70.3%
Q12026-03-3131.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$977.60K

N/A

Employees

2

N/A

Net Income

-$765.99K

+24.7%

EBITDA

-$765.99K

+24.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.53M

+64.9%

Total Debt

$0.00

N/A

Accounts Receivable

$7.81K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-57.40%

N/A

Return on Invested Capital

-64.27%

N/A

Free Cash Flow

-$804.28K

+13.2%

Operating Cash Flow

-$804.28K

+13.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NAOVNanoVibronix, Inc.
$1.90+1.06%
BDRXBiodexa Pharmaceuticals Plc
$1.64-2.38%
INMInMed Pharmaceuticals Inc.
$1.75-5.41%
VEROVenus Concept Inc.
$0.31+2.64%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.26-0.06%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$44.68+0.03%
MARAMara Holdings
$12.28-0.04%
JBLUJetBlue Airways
$5.23+0.05%

Questions About BBLG

What is the current price of Bone Biologics?

Bone Biologics is trading at $1.09 per share.

What is the 52-week range for Bone Biologics?

Over the past 52 weeks, Bone Biologics has traded between $1.05 and $4.13.

How much debt does Bone Biologics have?

As of the most recent reporting period, Bone Biologics reported total debt of $0.00.

How much cash does Bone Biologics have on hand?

Bone Biologics reported $4.53M in cash and cash equivalents in its most recent financial results.

What is Bone Biologics’s dividend yield?

Bone Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services